Directory of Pharma Companies and News
Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofiâ€™s programs in oncology and immunology.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
|2017-12-07||Sanofi explores combination treatments for multiple myeloma in new late-stage trials|
|2017-11-09||Sanofi, Principia agree to develop multiple sclerosis drug candidate|
|2017-11-02||Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditar...|
|2017-10-31||Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in a Phase 3 Study of People wit...|
|2017-10-27||Treatment Effects Maintained Over Five Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi...|
|2017-10-26||New Data Suggest Slowing of Cortical Gray Matter Atrophy with Sanofi Genzymeâ€™s AubagioÂ® (teriflunomide) is Associated wi...|
|2017-10-17||More than 30 Presentations of New Investigational Data from Sanofi Genzymeâ€™s Multiple Sclerosis Franchise to be Featured...|
|2017-10-16||Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eo...|
|2017-10-11||Internationally Acclaimed Writer and Executive Producer of HBOâ€™s The Night Of Reveals His Personal Story Detailing the H...|
|2017-09-28||Sanofi and Regeneron Announce Approval of DupixentÂ® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic D...|